NIMHD Mourns Clinical Director Reed
|NIMHD’s Dr. Eddie Reed, an award-winning physician and internationally recognized cancer researcher, died May 28.
Dr. Eddie Reed, an award-winning physician and internationally recognized cancer researcher at NIH, died May 28 at age 60 in Bethesda of liver cancer.
Reed had been clinical director at NIMHD since January 2013. He oversaw a combination of epidemiological, clinical and laboratory-based studies. He was building a multi- and inter-disciplinary research program geared to translating basic research into clinical trials and ultimately, interventions. He led the NIMHD effort in enhancing the recruitment and retention of minorities and other underserved populations in clinical trials.
“Dr. Reed’s critical work in anticancer chemotherapy has benefitted so many lives,” said NIMHD acting director Dr. Yvonne Maddox. “Throughout his distinguished career, Dr. Reed was committed to overcoming the challenges of health disparities among underserved populations, particularly with regard to access to care and recruitment in clinical trials.”
Prior to joining NIMHD, Reed served as professor of oncologic sciences and Abraham Mitchell distinguished investigator at the University of South Alabama’s Mitchell Cancer Institute, where he worked closely with the state of Alabama on life-saving cancer screening and control programs. At NCI, he previously served as a tenured senior investigator in the Division of Cancer Treatment, chief of the Clinical Pharmacology Branch (the first African-American branch chief at NCI) and chief of the Ovarian Cancer and Metastatic Prostate Cancer Clinic in the Division of Clinical Science. Reed also was director of the Mary Babb Randolph Cancer Center at West Virginia University and director of the Division of Cancer Prevention and Control at the Centers for Disease Control and Prevention.
Reed’s clinical research primarily focused on DNA damage and repair in cancer cells in response to pharmacological anticancer agents. He conducted more than four dozen phase I or phase II clinical trials of these agents and received two Public Health Service Commendation Medals for his work on the clinical development of the powerful anticancer agent paclitaxel. He also collaborated on numerous public health cancer prevention, screening and control programs, many of which were focused on reducing health disparities.
“Dr. Reed was an incredible researcher and clinician,” said NIMHD deputy director Dr. Joyce Hunter. “His contributions to cancer research are truly immeasurable.”
Born in Hughes, Ark., Reed received his undergraduate degree from Philander Smith College in Little Rock, Ark., and his medical degree from Yale University School of Medicine. He completed his internship and residency at Stanford University and an oncology fellowship at NCI. He was board-certified in internal medicine and had been listed as a Top Doctor by U.S. News & World Report. Reed served on the Institute of Medicine’s National Cancer Policy Forum from 2005-2008 and the National Advisory Council on Minority Health and Health Disparities.
He is survived by his wife, Dr. Meenakshi Reed.
Murphy To Direct
Dr. Stephanie J. Murphy has been named director, Division of Comparative Medicine (DCM) within the Division of Program Coordination, Planning, and Strategic Initiatives. She comes from Oregon Health & Science University, where she was a professor of anesthesiology & perioperative medicine.
Murphy received her V.M.D. and Ph.D. from the University of Pennsylvania. She completed a postdoctoral fellowship in the department of comparative medicine at Johns Hopkins and is a diplomate of the American College of Laboratory Animal Medicine.
After completing her training, Murphy joined the department of anesthesiology & critical care medicine at Johns Hopkins as an assistant professor. In 2003, she joined the research faculty at OHSU. Murphy has published numerous articles, reviews and book chapters related to her research and clinical interests. She has secured NIH and other funding for the past 17 years to support her research on sex differences and sex steroids in stroke.
As a board-certified laboratory animal veterinarian, Murphy brings a unique perspective to her new assignment. “DCM’s research supports animal models and resources, so I’d like to think that my training brings an added layer to the history I already have with DCM from the grantee perspective,” she said.
Lai To Head CSR Review Group
Dr. Patrick Lai has been named chief of the immunology integrated review group (IRG) at the Center for Scientific Review. He was most recently scientific reviewer officer for CSR’s immunity and host defense study section.
“Patrick has been a mainstay of the immunology IRG for many years,” said Dr. Seymour Garte, director of CSR’s Division of Physiological and Pathological Sciences. “He has served as acting chief on numerous occasions and his scientific background and experience made him the top candidate for the job.”
Lai will oversee 10 study sections, which review NIH grant applications that seek better understandings of the interactions, mechanisms and evolution of the immune system and its role in the prevention and treatment of disease.
Lai earned his Ph.D. in virology and immuno-logy from the University of Western Australia. After postdoctoral work in Ottawa, London and Zurich, he moved to the University of Nebraska Medical Center in Omaha, where he was an assistant professor. He conducted research on immune responses and the molecular biology of Epstein-Barr virus, human immunodeficiency virus and Borna disease virus.
He later became director of the Molecular Biology and Biotechnology Program and chairman of the bioscience department at Salem International University in Salem, W.Va. During his academic career, Lai published 47 articles, 10 chapters in books and holds 6 U.S. and international patents.
Two NIDDK Scientists Honored
NIDDK senior investigators Dr. Kenneth Jacobson (r) and Dr. Jurgen Wess (l) flank Dr. Richard R. Neubig, president of the American Society for Pharmacology and Experimental Therapeutics (ASPET) at an awards ceremony recently. Jacobson received the ASPET 2014 Goodman & Gilman Award in Drug Receptor Pharmacology. The award recognizes outstanding research in pharmacology of biological receptors that could provide a better understanding of the mechanisms of biological processes and provide the basis for drug development. Wess received the 2014 Pharmacia-ASPET Award for Experimental Therapeutics. It recognizes outstanding research in pharmacology and experimental therapeutics, basic laboratory or clinical research that has had or could have a major impact on the pharmacological treatment of disease.